{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T12:41:04Z","timestamp":1772628064185,"version":"3.50.1"},"reference-count":29,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2011,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>An adapted LMB 96 derived protocol for B\u2010cell non\u2010Hodgkin lymphoma (NHL) was implemented at the pediatric oncology unit of the Children Welfare Teaching Hospital in Baghdad (Iraq) from 2000 to present. The purpose was to evaluate the feasibility and efficacy of this intensive therapeutic regimen in a limited resource country.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients &lt;15 years of age with high grade B\u2010cell NHL were included. A modified LMB 96 regimen was employed with a reduction of cyclophosphamide and methotrexate dosages due to inadequate laboratory facilities and supportive care.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Between 2000 and 2005, 261 children with non\u2010lymphoblastic NHL were registered; 239 were eligible for the analysis. Two patients had stage I disease, 20 stage II, 179 stage III, and 38 stage IV. Fifty\u2010two patients (22%) had bulky disease. Twelve children were assigned to therapeutic group A (low risk), 184 to group B (intermediate risk), and 43 to group C (high risk). One hundred and eighty\u2010four patients (77%) had a complete response after the COP pre\u2010phase. Sixty\u2010nine patients (29%) died during treatment. Twenty\u2010nine patients abandoned treatment. At 24 months, the overall survival rate of the entire patient population was 66% (CI 95%: 62.2\u201370.6) and the event\u2010free survival rate 53.3% (CI 95%: 50.0\u201356.8).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The treatment schedule proved effective, but the treatment\u2010related mortality due to infections and metabolic complications was very high owing to the limited supportive care available. The high rate of treatment abandonment was also an important cause of failure, especially for children living far away from the hospital. Pediatr Blood Cancer 2011;56:560\u2013567. \u00a9 2010 Wiley\u2010Liss, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pbc.22905","type":"journal-article","created":{"date-parts":[[2010,12,2]],"date-time":"2010-12-02T01:13:20Z","timestamp":1291252400000},"page":"560-567","source":"Crossref","is-referenced-by-count":37,"title":["Treatment of children with B\u2010cell non\u2010Hodgkin lymphoma in a low\u2010income country"],"prefix":"10.1002","volume":"56","author":[{"given":"Maria Luisa","family":"Moleti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salma Abbas","family":"Al\u2010Hadad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mazin Faisal","family":"Al\u2010Jadiry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir Fadhil","family":"Al\u2010Darraji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raghad Majid","family":"Al\u2010Saeed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annalisa","family":"De Vellis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"Piciocchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Uccini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Fo\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Maria","family":"Testi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,12]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2007.1.285"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.12.1732"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1053\/beha.2002.0231"},{"key":"e_1_2_6_5_2","first-page":"3294","article-title":"Improved treatment results in childhood B\u2010Cell neoplasms with tailored intensification of therapy: A report of the Berlin\u2013Frankfurt\u2013Munster Group Trial NHL\u2010BFM 90","volume":"94","author":"Reiter A","year":"1999","journal-title":"Blood"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-0973"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.11.3370"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07144.x"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-036665"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-036673"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21003"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20989"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2004.08.001"},{"key":"e_1_2_6_14_2","first-page":"509","article-title":"Impact of international collaboration on the prognosis of childhood acute promyelocytic leukemia in Iraq","volume":"91","author":"Testi AM","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_6_15_2","first-page":"2112","article-title":"The Non Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classification of non\u2010Hodgkin's lymphomas: Summary and description of a Working Formulation for clinical usage","year":"1982","journal-title":"Cancer"},{"key":"e_1_2_6_16_2","first-page":"332","article-title":"Classification, staging and results of treatment of childhood non\u2010Hodgkin's lymphomas: Dissimilarities from lymphomas in adults","volume":"7","author":"Murphy SB","year":"1980","journal-title":"Semin Oncol"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O"},{"key":"e_1_2_6_19_2","first-page":"37","article-title":"Nonparametric confidence limits survival probabilities and median survival time","volume":"66","author":"Simon R","year":"1982","journal-title":"Cancer Treat Res"},{"key":"e_1_2_6_20_2","volume-title":"Applied logistic regression","author":"Hosmer DW","year":"1989"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc0803444"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20116"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200407000-00014"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21452"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.10322"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1136\/adc.61.10.1013"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1989.123"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.10.2998"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.3.697"},{"key":"e_1_2_6_30_2","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s00277-003-0608-2","article-title":"Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma\/leukemia before and after introduction of prophylactic use of urate oxidase","volume":"82","author":"W\u00f6ssmann W","year":"2003","journal-title":"Ann Hematol"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.22905","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.22905","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.22905","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T14:26:37Z","timestamp":1700490397000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.22905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["10.1002\/pbc.22905"],"URL":"https:\/\/doi.org\/10.1002\/pbc.22905","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12]]}}}